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Abstract—According to the fact that cancer diseases are 
leading causes of death all around the world, development of 
cancer fighting therapies is necessary. Beside the medical 
knowledge, there is an extra need for engineering approach 
to solve this complex problem. The aim of this paper is to 
design controller for tumor growth under angiogenic 
inhibition, which on the one hand minimizes the input signal 
as far as possible (in order to have less side effects and 
greater cost-effectiveness) and on the other hand results in 
appropriately low tumor volume. Since the model contains 
uncertainties and measurement noise, the controller was 
designed using modern robust control methodology. 
Choosing of the ideal system and the weighting functions 
were done in the light of physiological aspects. 
I. INTRODUCTION 
Cancer diseases are leading causes of death nowadays 
all around the world. In the EU the total predicted number 
of cancer deaths in 2013 is 1.314.236 compared with 
1.281.694 in 2009 [1]. In Hungary, cancer was the second 
most common cause of death after cardiovascular diseases 
in 2012 [2]. 
Protocols for medical treatment comprise constant drug 
dosage, which can be effective in terms of reducing the 
progression of the diseases; however, nowadays the 
problem seems more complex. From multidisciplinary 
point of view the aim is to design a controller which is on 
the one hand able to minimize the input signal as far as 
possible (in order to have less side effects and greater 
cost-effectiveness) and on the other hand results in 
appropriately low tumor volume. We have investigated 
the applicability of several control methods in this specific 
field and designed controllers using LQ control method 
and state observer [3], [4], flat control [5], and modern 
robust control method [6]. 
In biomedical applications experts always faced with 
two major problems: understanding the physiological 
behavior of a system and transform it into a model; and 
finding sufficiently sensitive methods and sensors to 
detect the required states and values. However, there 
always will be model uncertainties and measurement 
noises; thus, there is a need for systems which satisfy the 
requirements not only for its nominal values but also in 
the presence of perturbations. These aspects can be taken 
into account using H∞ control methodology that represents 
the goal of the current paper as well. 
The paper is organized as follows. In Section II, we 
review the biomedical background of the antiangiogenic 
therapy. In Section III, we analyze the nonlinear model of 
tumor growth under angiogenic inhibition, and describe a 
linear model which is acquired by working point 
linearization. Section IV contains the description of the 
design structure, the theoretical H∞ suboptimal solution, 
and the choice of the ideal system and the weighting 
functions in the light of physiological aspects. In Section 
V, we present the simulation results. The paper ends with 
the conclusion in Section VI. 
II. BIOMEDICAL BACKGROUND 
Angiogenesis is the process of forming new blood 
vessels, which occurs normally in the human body at 
specific times. During embryogenesis vasculogenesis 
plays an important role; however, angiogenesis also takes 
place in adults. The process of angiogenesis is precisely 
controlled by proangiogenic and antiangiogenic factors, 
thus, normally there is an angiogenic balance in the body. 
All cells need oxygen and nutrients, which can be 
picked up from nearby capillaries. Tumor cells are 
dividing rapidly, so there is an extra need for oxygen. 
When proliferation begins, small sized tumor can pick up 
enough oxygen – in this phase tumor is an avascular 
nodule (dormant), in a steady-state level of proliferating 
and apoptosing cells [7]. After a certain size (1-2 mm 
diameter), tumor development stops, because the diffusion 
of oxygen through tissues is limited. Tumor needs own 
blood vessels to grow, however forming new vessels is 
inhibited by the body's antiangiogenic factors. Tumor 
have to break through this strict control – the process 
when tumor become able to form own blood vessels is 
called angiogenic switch. This switch ensures exponential 
tumor growth. The aim of antiangiogenic therapy is to 
prevent tumors from forming new blood vessels, because 
without angiogenesis tumor growth is inhibited [8], [9]. 
III. DYNAMICAL MODEL OF TUMOR GROWTH UNDER 
ANGIOGENIC INHIBITION  
P. Hahnfeldt et al. created a dynamic model for tumor 
growth in antiangiogenic therapy [10]. In their experiment 
mice were injected with Lewis lung carcinoma cells and 
they have investigated the effect of three different 
angiogenic inhibitors (angiostatin, endostatin and TNP-
470). The original model was analyzed and modified in 
several studies [11], [12], [13]. The most important 
alteration is the continuous infusion therapy [12], where 
the input (the inhibitor administration rate) is equal to the 
concentration of administered inhibitor (serum level of 
inhibitor). 
The model which takes into account the continuous 
infusion therapy is the following second-order system: 
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where  x1 is the tumor volume (mm3), x2 is the endothelial 
volume (mm3), g is the concentration of the administered 
inhibitor (mg/kg). The model contains the following 
parameters: λ1 is the tumor growth rate (1/day), b is the 
stimulatory capacity of the tumor to the vasculature 
(1/day), d is the endogenous inhibition of previously 
generated vasculature (1/day·mm2), e is the 
antiangiogenic effect of the administered inhibitor on the 
tumor vasculature (kg/day·mg). 
Parameter values for the considered Lewis lung 
carcinoma and the mice used in the experiment are [10]:  
λ1 = 0.192 1/day, b = 5.85 1/day, d = 0.00873 1/day·mm2. 
The experiment has shown that the most effective 
inhibitor was endostatin; therefore, we have applied this 
antiangiogenic drug in controller design (eendostatin = 0.66 
kg/day·mg). 
From equation (1) it can be seen that the system is in 
steady-state if the tumor volume and the vascular volume 
are equal. (We will use ‘endothelial’ and ‘vascular’ words 
as synonyms during the article). Steady-state can be 
reached in two different ways (Fig. 1). Tumor growth 
without antiangiogenic therapy leads to high steady-state 
tumor volume (1.734ˇ104 mm3) and it represents the lethal 
steady-state case. Using angiogenic inhibition, tumor size 
can be reduced from a high tumor volume to a low value. 
In the lower part of Fig. 1 we have simulated the effect of 
constant 5 mg/kg endostatin inhibition. 
Since H∞ control design requires a linear nominal 
model, we have applied working point linearization [14] 
in the g0 = 0 working point. The matrices of the linear 
model are: 
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The assessed working point is x1 = x2 = 100 mm3. 
Eigenvalues of the linearized system are p1 =-1.2384 and 
p2 = 0.8584; because of p1 has positive real part, the 
system is unstable. Investigating the controllability and the 
observability matrices, we have found that they are full 
rank for every x1 ≠ 0, thus the linearized system is 
controllable and observable in every working point [4]. 
 
IV. H∞ CONTROL DESIGN 
A. Design structure 
For controller design, we have created the closed-loop 
interconnection structure (Fig. 2). 
 
Figure 1. Tumor growth without and under angiogenic inhibition 
 
The closed-loop system includes the feedback structure 
of the nominal model Gn. K is the two-degrees of freedom 
controller, which consists of two parts: Kr is the 
feedforward branch and Ky is the feedback branch. 
Differences between the nominal model and the real 
system are taken into account using input multiplicative 
uncertainty, Gunc [15]: 
))(()()( sIsWsG uncuncunc Δ+⋅=  (8) 
Weighting function Wn seeks to minimize the influence 
of sensor noise. Limitation of the control input is achieved 
by the weighting function Wu, which penalizes larger 
deflections. Ideal system is described by Tid transfer 
function. Weighting function Wperf seeks to penalize 
differences between the output of the nominal model and 
the ideal plant. 
Signals of the system are the following: r is the 
reference signal, u is the control input, y is the output of 
the nominal model, n is the measurement noise, e is the 
modeling error, d is the disturbance caused by the 
uncertainty of the model, zu is the penalized control input 
and ze is the penalized difference between the output of 
the nominal model and the ideal model. 
The generalized structure of H∞ control design is 
formulated in Δ-P-K structure (Fig. 3). The detailed  
Δ-P-K structure is described as follows:  
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P is called the generalized plant and partitioned as: 
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Input of the generalized plant is: 
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Figure 2. The closed-loop interconnection structure for controller design 
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where w* = [r n]T is the external input and wmin = [d w*]T. 
Output of the generalized plant is: 
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where z* = [ze zu]T is the external output to be penalized 
and zmin = [e  z*]T. 
The closed-loop function M can be derived as the lower 
linear fractional transformation of the pair (P,K): 
( )[ ] minmin211221211min ),( wKPFwPKPIKPPz l=−+= −  (13) 
),( KPFM l= (14) 
B. H∞ suboptimal solution 
The objective is to find a stabilizing controller K to 
minimize the output zmin, in the sense of ||w||∞ ≤ 1. It is 
equivalent to minimizing the H∞-norm of M from wmin to 
zmin: 
,||),(||min
∞
KPFlKs
 (15) 
where Ks is an element of the set of stabilizing K 
controllers; this is called the H∞ optimization problem 
[16]. Since the solution of the optimization problem is not 
obvious, in practice, it is usually satisfactory to find a 
stabilizing controller K such the H∞-norm of the closed-
loop function is less than a given positive number [16]: 
,||),(|||||| γ<=
∞∞
KPFM l  (16) 
where γ > γ0 = minKs||Fl(P,K)||∞; it is called as the H∞ 
suboptimal problem. 
System-performance specifications can usually be 
interpreted as a reduction of z* with respect to w*. 
Robustness and performance can be investigated by the 
partition blocks of M: 
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The scope of the H∞ controller design is to guarantee 
robust performance of the system. This can be realized by 
fulfilling the conditions of robust stability and nominal 
performance. To guarantee nominal stability the system 
must be internally stable, which means that the created 
transfer function is stable from all inputs to all outputs. 
Robust stability is achieved by fulfilling the following 
condition: 
1|||| 11 ≤∞M  (18) 
Nominal performance is achieved if the performance 
objective is satisfied: 
1|||| 22 ≤∞M  (19) 
The upper linear fractional transformation of the pair 
(M, Δ) can be described as: 
( )[ ] *),(** 121112122 wMFwMMIMMz u Δ=Δ−Δ+= − (20) 
Robust performance is achieved by fulfilling the 
following condition: 
1||),(|| <Δ
∞
MFu  (21) 
C. Choosing of the ideal system and the weighting 
functions in the light of physiological aspects 
From engineering point of view, the ideal system (Tid) 
is needed to be a fast system for fast reduction of the 
tumor volume. Nevertheless, on the one hand it is 
physically impractical, on the other hand fast transients 
need high control signal and in medical treatments the 
input is always limited. Besides these, researches have 
shown that in the case of antiangiogenic therapy low-dose 
treatments can be more effective ([17] states it exactly in 
the context of Lewis lung carcinoma). According to the 
fact that tumor regression has exponential characteristics, 
our ideal system was found to have a relatively slow 
exponential decay: 
,
1
)(
+
=
sT
KsTid  (22) 
where K is the initial tumor volume and T is the time 
constant of the ideal system (T = 100 days). Weighting 
function Wu (which penalizes large deflections of the 
control input) was chosen to constant value and we have 
run iteration to find the greatest possible value to penalize 
deflections. Finally we set Wu = 0.02. 
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Figure 3. The generalized Δ-P-K structure 
 
 
Figure 4. Weighting functions of the controller 
 
Sensor-noise, as a wide-band signal, can be modeled 
with a constant value. The effect of the weighting function 
Wn was investigated in the range of [0.0 0.2], Section V 
contains the results of this analysis. 
In the case of weighting functions Wunc and Wperf, tuning 
of the crossover frequencies was carried out to reach 
better performance and robustness. 
5.0
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+
+
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s
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01.0=perfW (24) 
The chosen weighting functions can be seen in Fig. 4. 
V. SIMULATION RESULTS 
Frequency domain analysis (Fig. 5) showed that the 
conditions of robust stability (18), nominal performance 
(19) and robust performance (21) are fulfilled, because all 
the corresponding norms are smaller than 1 for every 
frequency. 
The reached γ value was 0.0781 and the K controller 
was stable, thus the designed structure provides a 
suboptimal H∞ solution. According to the minimal size 
criteria for diagnosis in the case of Lewis lung carcinoma 
(tumor size has to be bigger than 3 cm [18]) and assuming 
a spherical shape, simulations were run from the initial 
tumor volume x0 = 14137 mm3. 
Time domain analysis showed that control input 
saturation is necessary, because one-off high dose can be 
tolerated by the patient; however, continuous dosage of 
angiogenic inhibitor is limited in concentration to around 
10 mg/kg [19]. The saturation, which was resulting in the 
least possible control signal, but still effective H∞ control, 
is 13 mg/kg; every simulation results were run with this 
value. 
The effect of the weighting function Wn was 
investigated in the range of [0.0 0.2], since subcutaneous 
tumor volume measurement is usually carried out by 
calipers. Width and length of the tumor can be measured, 
but the third dimension is estimated; and tumor volume is 
approximated with a spherical shape or an ellipsoid [20]. 
The results have shown that the designed H∞ controller 
can handle the sensor noise in a robust way until 15%: we 
have found that if Wn  ≤ 0.15, tumor volume (output of the 
system) decreased exactly the same rate in every cases. 
Above this value, the control signal was not applicable. 
This result also shows how important the precise tumor 
volume measurement is, and if it is possible, Magnetic 
Resonance Imaging (MRI) has to be preferred as 
measurement method against to caliper [21]. 
Effect of the initial tumor volume at the beginning of 
the therapy was examined in the [100 17340] mm3 range. 
The results are shown in Fig 6. Steady-state tumor volume 
is independent from the initial tumor volume; in every 
case tumor volume was 25.6 mm3 ± 0.1% (Fig 6.a). 
Steady-state inhibitor concentration (Fig 6.b) has showed 
the same result, viz. minimal deviation (8.759 mg/kg ± 
0.07%). It is clear that the period of maximal inhibitor 
dose (Fig 6.c) have to increase as the simulations start 
from higher initial tumor volumes to ensure the 
appropriate steady-state tumor volume. However, a 
breakpoint can be determined at 2000 mm3: below this 
value, initial tumor value has greater impact on the 
maximal inhibitor period than above this point. 
Similar results can be seen in (Fig 6.d); total 
concentration of the administered inhibitor depends more 
on initial tumor volume below the 2000 mm3 breakpoint 
than above (of course the former last two functions are not 
independent). Summarizing the results of these figures: at 
lower initial working points the dynamics of the change is 
larger and the controller should administer more inhibitor; 
however, nearly the same tumor outputs can be provided. 
We have compared our previous result, when optimal 
LQ controller was designed for angiogenic inhibition of 
tumor growth [4], with the H∞ suboptimal solution. The 
outcome can be seen in Fig. 7. The numerical results are 
the following. Steady-state tumor volume: VLQ = 7.491 
mm3, VH∞ = 25.64 mm3. 
 
 
Figure 5. Robust Performance, Robust Stability and  
Nominal Performance 
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Figure 6. Investigating the effect of different working points on the  
a) steady-state tumor volume,   
b) steady-state inhibitor concentration, 
c) period of maximal inhibitor dose and 
d) total concentration of the administered inhibitor 
 
 
Figure 7. Comparison of control inputs and tumor volumes in the 
cases of Linear Quadratic optimal control and  
suboptimal Robust Control method 
Steady-state inhibitor concentration: SCLQ = 3.093 
mg/kg, SCH∞ = 8.768 mg/kg. Period of maximal inhibitor 
dose: TLQ = 60 days, TH∞ = 64 days. Total concentration 
of the administered inhibitor: SCLQ = 915 mg/kg, SCH∞ = 
1173 mg/kg. As it would expected, LQ optimal control 
provides better results, but only in the case of good model 
identification and minimal sensor noise. If the system 
contains significant uncertainties and the measurement 
noise is large, only robust control method can provide 
near-optimal results. Last but not least, we have 
simulated and compared the changes in full-grown 
tumor volume after making the diagnosis (14137 
mm3) in three different cases; Fig. 8. shows the 
results. The first case was a therapy when the 
inhibitor was administered by the H∞ controller. In the 
second case the therapy was based on the Hungarian 
OEP protocol for antiangiogenic monotherapy [22]. 
The third case was the simulation without therapy. 
From Fig. 8 it is clear, that the intermittent dosing 
used by the chemotherapy protocol is not effective. 
The tumor volume reduced slightly as a result of one-
day dose, but between the treatment phases, tumor grows 
back again. At the end of the whole treatment period, 
there is no large difference between the therapy with OEP 
protocol and the case without therapy. 
VI. CONCLUSION 
H∞ controller was designed for the problem of tumor 
growth under angiogenic inhibition, considering the 
physiological aspects. Robust stability, nominal 
performance and robust performance were achieved. 
Frequency domain analysis and time domain analysis 
were carried out. We have investigated the effect of the 
sensor noise weighting function on the robustness. We 
have also examined the effect of the initial tumor volume 
on the steady-state tumor volume, on the steady-state 
inhibitor concentration, on the period of maximal inhibitor 
dose and on the total concentration of the administered 
inhibitor. We have compared the results of the H∞ 
controller with the results of LQ optimal control and the 
therapy with OEP protocol. Further research will focus on 
other control strategies like fuzzy control [23], robust 
multiobjective optimization questions [24], system 
identification problems, but real world applicability 
challenges [25] as well. 
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